ReviewThe Journal of endocrinology2012
Unraveling oxyntomodulin, GLP1's enigmatic brother.
Review in The Journal of endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 125 citations in OpenAlex.
- Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS.The Journal of clinical endocrinology and metabolism · 2021Trial
- Feasibility of Multi-Wavelength LED Irradiation on the Skull and Preliminary Glycemic Outcomes in Individuals with Type 2 Diabetes: A Prospective Pilot Study.Life (Basel, Switzerland) · 2026Article
- Future Directions in the Medical Treatment of Obesity: A Narrative Review.Advances in therapy · 2026Review
- The role and implications of mammalian cellular circadian entrainment.FEBS letters · 2026Review
- Systematic metabolite screening identifies functional regulators of the adenosine A2A receptor.Communications chemistry · 2025Article
- Microbiota-Gut-Brain Axis and Impaired Satiety in Individuals with Obesity: A Potentially Bidirectional Association.Current nutrition reports · 2025Review
- Dissociation of plasma oxyntomodulin levels from anthropometric measures and metabolic markers in women with polycystic ovary syndrome.Archives of endocrinology and metabolism · 2025Article
- Principles and Biomedical Applications of Self-Assembled Peptides: Potential Treatment of Type 2 Diabetes Mellitus.Pharmaceutics · 2024Review
- Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease.American journal of physiology. Endocrinology and metabolism · 2024Review
- Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.International journal of molecular sciences · 2024Review
- Dietary Fibre for the Prevention of Post-Pancreatitis Diabetes Mellitus: A Review of the Literature and Future Research Directions.Nutrients · 2024Review
- Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics.Current pharmaceutical biotechnology · 2024Review
- Structural analysis of the dual agonism at GLP-1R and GCGR.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors.Journal of chemical information and modeling · 2023Article
- Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review.Biomedicines · 2023Review
- G protein-coupled receptors and obesity.Frontiers in endocrinology · 2023Review
- Metabolism-based approaches for autosomal dominant polycystic kidney disease.Frontiers in molecular biosciences · 2023Review
- The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury.Acta pharmaceutica Sinica. B · 2022Review
- (D-Ser2) oxyntomodulin recovers hippocampal synaptic structure and theta rhythm in Alzheimer's disease transgenic mice.Neural regeneration research · 2022Article
- Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxyntomodulin (OXM) is a peptide secreted from the L cells of the gut following nutrient ingestion. OXM is a dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) combining the effects of GLP1 and glucagon to act as a potentially more effective treatment for obesity than GLP1R agonists. Injections of OXM in humans cause a significant reduction in weight and appetite, as well as an increase in energy expenditure. Activation of GCGR is classically associated with an elevation in glucose levels, which would be deleterious in patients with T2DM, but the antidiabetic properties of GLP1R agonism would be expected to counteract this effect. Indeed, OXM administration improved glucose tolerance in diet-induced obese mice. Thus, dual agonists of the GCGR and GLP1R represent a new therapeutic approach for diabetes and obesity with the potential for enhanced weight loss and improvement in glycemic control beyond those of GLP1R agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.